Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07258849 · ClinicalTrials.gov registry record · Phase 1

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

A Phase 1 study of Healthy and Rheumatoid Arthritis (RA), sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 1
Development phase
134
Enrollment target
9
Study locations

NCT07258849 is a Phase 1 study of Healthy and Rheumatoid Arthritis (RA) that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 134 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (79% lower). The trial reports 9 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07258849, a Phase 1 study of Healthy and Rheumatoid Arthritis (RA), is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 1
Development phase
134 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA). The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 33 weeks excluding screening.

Conditions Studied

Healthy Rheumatoid Arthritis (RA)

Interventions

  • DRUG Placebo
  • DRUG LY4213663

Study Locations (9)

Florida

  • Clinical Research of West Florida, Inc. (Clearwater) - Clearwater
  • GNP Research at Mark Jaffe, MD - Cooper City
  • Fortrea Clinical Research Unit - Daytona Beach
  • AGA Clinical Trials - Hialeah
  • Advanced Pharma CR, LLC - Miami
  • Floridian Clinical Research - Miami Lakes

Alabama

  • Pinnacle Research Group, LLC - Anniston

Arizona

  • Arizona Research Center - Phoenix

Nevada

  • Oasis Clinical Research - Las Vegas

Trial Details

FieldValue
Enrollment Target 134 participants
Start Date 2025-12-02
Est. Completion 2028-03
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07258849

The ClinicalTrials.gov registry entry for NCT07258849 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (79% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07258849 reports 9 study locations spanning 4 distinct geographic areas - top geographies include Florida, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT07258849 about?

NCT07258849 is a clinical study titled "A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis". The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA). The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the ...

What is the current status of trial NCT07258849?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2025-12-02. Estimated completion is 2028-03.

What conditions does trial NCT07258849 study?

This clinical trial studies the following conditions: Healthy, Rheumatoid Arthritis (RA).

What interventions are being tested in trial NCT07258849?

The interventions under investigation include: Placebo (DRUG), LY4213663 (DRUG).

Who is sponsoring clinical trial NCT07258849?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07258849 being conducted?

This trial has 9 study locations across Alabama, Arizona, Florida, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy

All registered trials for this condition

Rheumatoid Arthritis (RA)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.